Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Neurology | Musculoskeletal | Family Medicine
Disease Category: Fibromyalgia
Location: United States, OK
A Study for the Treatment of Subjects with Fibromyalgia
This trial's participation duration is 21 weeks where
subjects will be seen in the clinic for a total of 12 visits.
Primary outcome is for a decrease in pain from fibromyalgia due to
the study drug.
Patient Inclusion Criteria
- Male or female subject must be 18 years of age or older and
meets the ACR criteria for fibromyalgia.
- Other inclusion criteria apply
Patient Exclusion Criteria
- Subject has Major Depressive Disorder, Bipolar, or other
psychotic disorder and cannot safely discontinue use of
- Subject has Rheumatic disease in addition to fibromyalgia or
other painful conditions that would interfere with the ability to
measure change on any outcome measures associated with stiffness
and muscle weakness.
- Other exclusion criteria apply
Qualified participants will receive, at not charge, study
medication, study-related medical care, and laboratory
If you are interested in this, or any other studies we currently
have enrolling, please contact us for further information.
Rachel Waldrop, Director of Clinical Research
Health Research Institute
1044 S.W. 44th Street
Oklahoma City, OK 73109
Research Center Information: Health Research Institute
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these